Role of Nanotechnology for Targeted Therapy in Cancer

Nanotechnology plays a vital role in the development of targeted cancer therapies, offering the potential for more effective, accurate, and minimally invasive options for treatment. In order to improve drug accumulation within cancer cells and reduce exposure to healthy tissues, nanoparticles can be designed to deliver anticancer medications directly to the site of action. This targeted drug delivery increases the therapeutic efficacy and reduces systemic side effects. Compared to traditional therapies, nanocarriers are more effective at reaching tumor microenvironments and overcoming biological barriers due to their small size (between 1 and 100 nanometers). Nanoparticles can be loaded with a variety of agents, including chemotherapeutic agents, imaging agents, and photosensitizers, which allow for the combination of drug therapies and real-time therapy efficacy assessment. In addition to delivering drugs intracellularly, nanocarriers can also avoid drug efflux processes and can help some malignancies overcome resistance. This technology ensures localized drug therapy activation by enabling the design of nanocarriers that deliver drugs in response to specific stimuli inside the tumor microenvironment, such as temperature, enzymes, or acidic pH. With the help of nanotechnology, it is possible to develop theranostics that integrate both therapy and diagnostic imaging which enable real-time evaluation of therapeutic results and personalized treatment plans. Therefore, nanotechnology enhances the efficacy, safety, and customization of cancer treatment by enabling focused therapy, minimizing side effects, and incorporating diagnostic capabilities. These nanoplatforms are being optimized for clinical translation and better patient outcomes through ongoing research.